Spectrometry News and Research

RSS

IRIC scientists identify vitamin B3 as potential antifungal treatment

A team of scientists from the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal have identified vitamin B3 as a potential antifungal treatment. Led by IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre Thibault, in collaboration with Alaka Mullick, from the Biotechnology Research Institute of the National Research Council Canada, the study is the subject of a recent article in Nature Medicine.

9 Jul 2010

Novel molecular pathway that regulates invasive growth, metastasis in ER-positive breast cancer discovered

A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.

6 Jul 2010

USPTO grants Vermillion Alzheimer's disease biomarker patent

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Biomarkers for Alzheimer's disease" to the Company.

29 Jun 2010

Hydrophobic proteins may serve as biomarkers for treating colorectal cancer

Colorectal cancer, cancer of the colon and rectum, is a common cause of mortality worldwide. Statistical data showed that the number of deaths caused by colorectal cancer is increasing in both men and women.

25 Jun 2010

Biodesix awarded US patent for VeriStrat serum test

Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy.

22 Jun 2010

Biotage launches ISOLUTE SLE+ sample preparation columns

Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announced the introduction of ISOLUTE SLE+ High-Performance Supported Liquid Extraction sample preparation columns. The announcement occurred during the 58th ASMS Conference on Mass Spectrometry and Allied Topics in Salt Lake City, Utah USA.

22 Jun 2010

Bone samples act as the ultimate biomarker for environmental pollution: Researchers

Exposure to chemical pollutants is of growing concern to regulators, health workers, and environmentalist groups alike. Now, researchers in the US and Russia have demonstrated that samples of human bone can act as a biological marker for dozens of metals and toxic elements across the periodic table. They describe details in a study published in the International Journal of Environment and Health.

18 Jun 2010

NSF awards Florida State University $17.5M grant to build 21-tesla magnet system for large molecule analyses

The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.

16 Jun 2010

BIOCIUS Life Sciences, BlueSky Biotech collaborate to offer Sirtuin pre-validated assay solution

BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry's only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully-validated in a label-free functional assay.

16 Jun 2010

Correlogic Systems' OvaCheck blood test for detection of epithelial ovarian cancer receives CE Mark

Correlogic Systems, Inc. announced today that OvaCheck, the company's blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test. The path is now cleared for the test to be made available to patients in Europe through their physicians.

9 Jun 2010

Agilent Technologies selected as primary provider of gas-phase testing instruments for 2010 World Cup

Agilent Technologies Inc. today announced it has been selected by the South African Doping Control Laboratory as the primary provider of gas-phase testing instruments for the 2010 World Cup. The South African Doping Control Laboratory is certified by the World Anti-Doping Agency and will be responsible for all doping testing during the competition.

8 Jun 2010

DOE program to develop new imager for improving reliability of cancer therapy using heavy-ion beams

In 2008 the Nuclear Science Division (NSD) of the U.S. Department of Energy's Lawrence Berkeley National Laboratory launched the Applied Nuclear Physics program, headed by NSD's Kai Vetter upon his return to Berkeley after six years with Lawrence Livermore National Laboratory. One of the goals of Applied Nuclear Physics is to take experimental principles and equipment created for basic research and develop them into tools that can address practical needs like cancer therapy and homeland security.

5 Jun 2010

Small molecule ramps up interferon production in host cells, launching potent immune response

Many disease-causing microbes carry pumps that expel antibiotics, making the bugs hard to kill with standard drugs. Ironically, these same pumps could be the bugs' Achilles heel.

28 May 2010

Pressure BioSciences signs CRADA with AFIP, ARP and VA

Pressure BioSciences, Inc. today announced that it has signed a Cooperative Research and Development Agreement ("CRADA") with the Armed Forces Institute of Pathology ("AFIP"), the American Registry of Pathology ("ARP"), and the Department of Veterans Affairs ("VA").

27 May 2010

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

Pacific Biomarkers, Inc. has been awarded a contract by a leading multinational pharmaceutical company to provide essential laboratory data for an adaptive Phase I cardiovascular trial. This study is part of a major drug-development program to evaluate an innovative new treatment to reduce recurrent cardiovascular events associated with acute coronary syndrome.

27 May 2010

Agilent Technologies, Stemina Biomarker Discovery to accelerate metobolomic research

Agilent Technologies Inc. and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina's metobolomic research. Stemina uses metabolomic analysis of stem cells for the discovery of biomarkers for use in drug screening and drug development.

25 May 2010

Waters introduces new TQ-S and G2 QTof mass spectrometers for Xevo MS platform

Waters Corporation introduced today two new mass spectrometers for its Xevo MS platform – the Xevo TQ-S and Xevo G2 QTof – that bring a step change in performance to benchtop mass spectrometry. The product introductions were made at the 58th annual meeting of the American Society for Mass Spectrometry (ASMS).

25 May 2010

Lithium reduces brain inflammation by adjusting metabolism of DHA: Researchers

Though it has been prescribed for over 50 years to treat bipolar disorder, there are still many questions regarding exactly how lithium works. However, in a study appearing in this month's Journal of Lipid Research, researchers have provided solid evidence that lithium reduces brain inflammation by adjusting the metabolism of the health-protective omega-3-fatty acid called DHA.

24 May 2010

New MALDI molecular imaging system offers spatial analysis of target metabolites

At the 58th ASMS Conference on Mass Spectrometry and Allied Topics, Bruker today announces a novel MALDI molecular imaging system based on the extreme performance of the solariX FTMS.